<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25424925</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.</ArticleTitle><Pagination><StartPage>2220</StartPage><EndPage>2226</EndPage><MedlinePgn>2220-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/hv.29123</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) plays an important role in hand, foot, and mouth disease (HFMD), which recently caused the death of hundreds of children in the Asia-Pacific region. However, there are no specific treatments available for EV71 infections; thus, a safe and effective vaccine is needed urgently. In this study, we developed an effective and economical method for producing EV71 polyprotein (P1 protein) in Pichia pastoris. Furthermore, we evaluated the potential of P1 protein as a candidate vaccine against EV71 virus. The data revealed that P1 protein induced persistent high cross-neutralization antibodies for different EV71 subtypes, and elicited significant splenocyte proliferation. The high levels of interleukin-10(IL-10) and interferon-gamma (IFN-&#x3b3;) showed that P1 protein induced Th1 and Th2 immune responses. Interestingly, vaccinating female mice with the P1 protein conferred cross-protection against different EV71 subtypes to their neonatal offspring.Compared with heat-inactivated EV71, the P1 protein elicited improved humoral and cellular immune responses and showed good cross-protection with different EV71 subtypes. Therefore, the EV71-P1 protein produced by P. pastoris is a promising candidate vaccine against EV71.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>a College of life science; Jianghan University; Wuhan, Hubei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Xiao-ling</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shi-li</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Qi-ying</ForeName><Initials>QY</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xian-xun</ForeName><Initials>XX</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020815">Polyproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010843" MajorTopicYN="N">Pichia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020815" MajorTopicYN="N">Polyproteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">P1 polyprotein</Keyword><Keyword MajorTopicYN="N">Pichia pastoris</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">immunogenicity vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25424925</ArticleId><ArticleId IdType="pmc">PMC4896795</ArticleId><ArticleId IdType="doi">10.4161/hv.29123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. . An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129:304 - 9; http://dx.doi.org/10.1093/infdis/129.3.304; PMID: 4361245</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Li L, Liu Y, Ge H, Wang X, Hu J, Wu B, Fu J, Zhang Z, Chen X, et al. . . Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China. Virol J 2012; 9:248; http://dx.doi.org/10.1186/1743-422X-9-248; PMID: 23102275</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-248</ArticleId><ArticleId IdType="pmc">PMC3545860</ArticleId><ArticleId IdType="pubmed">23102275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. . Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 2007; 120:e244 - 52; http://dx.doi.org/10.1542/peds.2006-3331; PMID: 17671037</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyoshi K, Suga T, Mori A. . Enteroviruses in patients experiencing multiple episodes of hand, foot, and mouth disease in the same season in Kobe, Japan, 2011. Jpn J Infect Dis 2012; 65:459 - 61; http://dx.doi.org/10.7883/yoken.65.459; PMID: 22996228</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.65.459</ArticleId><ArticleId IdType="pubmed">22996228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VT. . The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010; 14:e1076 - 81; http://dx.doi.org/10.1016/j.ijid.2010.07.006; PMID: 20952237</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D, et al. . . The persistent circulation of enterovirus 71 in People&#x2019;s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011; 6:e25662; http://dx.doi.org/10.1371/journal.pone.0025662; PMID: 21980521</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang H, Ding S, Wang X, Chen X, Wo Y, Wang L, Huang D, Liu W, Cao W. . Prevalence of enteroviruses in children with and without hand, foot, and mouth disease in China. BMC Infect Dis 2013; 13:606; http://dx.doi.org/10.1186/1471-2334-13-606; PMID: 24370001</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-13-606</ArticleId><ArticleId IdType="pmc">PMC3890605</ArticleId><ArticleId IdType="pubmed">24370001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo RL, Shih SR. . Strategies to develop antivirals against enterovirus 71. Virol J 2013; 10:28; http://dx.doi.org/10.1186/1743-422X-10-28; PMID: 23339605</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-28</ArticleId><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="pubmed">23339605</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Lu J, Lu J. . Enterovirus 71 vaccine: close but still far. Int J Infect Dis 2010; 14:e739 - 43; http://dx.doi.org/10.1016/j.ijid.2009.12.002; PMID: 20400350</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2009.12.002</ArticleId><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="pubmed">20400350</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. . Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995; 39:195 - 205; http://dx.doi.org/10.1016/0168-1702(95)00087-9; PMID: 8837884</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. . An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26:91 - 107; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00601.x; PMID: 12007645</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. . DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007; 5:6; http://dx.doi.org/10.1186/1479-0556-5-6; PMID: 17445254</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Wu CN, Shih SR, Ho MS. . Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 2002; 20:2485 - 93; http://dx.doi.org/10.1016/S0264-410X(02)00182-2; PMID: 12057603</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00182-2</ArticleId><ArticleId IdType="pubmed">12057603</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, et al. . . Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010; 28:7444 - 51; http://dx.doi.org/10.1016/j.vaccine.2010.08.080; PMID: 20831911</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. . Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007; 9:1299 - 306; http://dx.doi.org/10.1016/j.micinf.2007.06.002; PMID: 17890123</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. . Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855 - 62; http://dx.doi.org/10.1016/j.vaccine.2008.01.058; PMID: 18329759</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. . Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000; 7:523 - 8; http://dx.doi.org/10.1007/BF02253368; PMID: 11060501</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02253368</ArticleId><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Deng C, Wan J, Zhu L, Leng Q. . Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J 2011; 8:306; http://dx.doi.org/10.1186/1743-422X-8-306; PMID: 21679417</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-306</ArticleId><ArticleId IdType="pmc">PMC3142239</ArticleId><ArticleId IdType="pubmed">21679417</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, Chiang YP, Chiang BL, Lee CY, Huang LM. . Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006; 60:466 - 71; http://dx.doi.org/10.1203/01.pdr.0000238247.86041.19; PMID: 16940249</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000238247.86041.19</ArticleId><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Juhela S, Hy&#xf6;ty H, L&#xf6;nnrot M, Roivainen M, Simell O, Ilonen J. . Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol 1998; 54:226 - 32; http://dx.doi.org/10.1002/(SICI)1096-9071(199803)54:3&lt;226::AID-JMV14&gt;3.0.CO;2-F; PMID: 9515773</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199803)54:3&lt;226::AID-JMV14&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">9515773</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Ang RX, Alonso S, Chow VT, Quak SH, Poh CL. . Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in Western blots. Clin Microbiol Infect 2008; 14:286 - 8; http://dx.doi.org/10.1111/j.1469-0691.2007.01904.x; PMID: 18076666</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2007.01904.x</ArticleId><ArticleId IdType="pubmed">18076666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, et al. . . Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008; 26:2882 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.03.041; PMID: 18450335</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.041</ArticleId><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. . Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20:895 - 904; http://dx.doi.org/10.1016/S0264-410X(01)00385-1; PMID: 11738755</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Jiang S, Wang Y. . Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun 2013; 430:387 - 93; http://dx.doi.org/10.1016/j.bbrc.2012.11.035; PMID: 23159634</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.11.035</ArticleId><ArticleId IdType="pubmed">23159634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT, Kwang J. . Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J 2012; 9:55; http://dx.doi.org/10.1186/1743-422X-9-55; PMID: 22361222</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-55</ArticleId><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Bai Y, Liu W, Xiao X, Huang Y, Cen S, Chan PK, Sun X, Sheng W, Zeng Y. . Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol 2013; 13:287; http://dx.doi.org/10.1186/1471-2180-13-287; PMID: 24320792</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-13-287</ArticleId><ArticleId IdType="pmc">PMC4029445</ArticleId><ArticleId IdType="pubmed">24320792</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Ying X, Huang H, Zhou S, Huang Q. . Expression and purification of enterovirus type 71 polyprotein P1 using Pichia pastoris system. Virol Sin 2012; 27:254 - 8; http://dx.doi.org/10.1007/s12250-012-3256-7; PMID: 22899434</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-012-3256-7</ArticleId><ArticleId IdType="pmc">PMC8218036</ArticleId><ArticleId IdType="pubmed">22899434</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuBakar S, Sam IC, Yusof J, Lim MK, Misbah S, MatRahim N, Hooi PS. . Enterovirus 71 outbreak, Brunei. Emerg Infect Dis 2009; 15:79 - 82; http://dx.doi.org/10.3201/eid1501.080264; PMID: 19116058</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1501.080264</ArticleId><ArticleId IdType="pmc">PMC2660687</ArticleId><ArticleId IdType="pubmed">19116058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih SR, Liu CC, Wu MH. . The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 2002; 34:Suppl 2 S52 - 7; http://dx.doi.org/10.1086/338819; PMID: 11938497</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338819</ArticleId><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. . Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003; 9:78 - 85; http://dx.doi.org/10.3201/eid1301.020112; PMID: 12533285</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Takebe Y, Kamarulzaman A. . Emerging and re-emerging viruses in Malaysia, 1997-2007. Int J Infect Dis 2009; 13:307 - 18; http://dx.doi.org/10.1016/j.ijid.2008.09.005; PMID: 19010076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2008.09.005</ArticleId><ArticleId IdType="pmc">PMC7110734</ArticleId><ArticleId IdType="pubmed">19010076</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, et al. . . Enterovirus 71 outbreak in the People&#x2019;s Republic of China in 2008. J Clin Microbiol 2009; 47:2351 - 2; http://dx.doi.org/10.1128/JCM.00563-09; PMID: 19439545</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, et al. . . Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 2014; 14:308 - 18; http://dx.doi.org/10.1016/S1473-3099(13)70342-6; PMID: 24485991</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, et al. . . An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009; 44:262 - 7; http://dx.doi.org/10.1016/j.jcv.2009.02.002; PMID: 19269888</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.02.002</ArticleId><ArticleId IdType="pubmed">19269888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, Wang SM, Lei HY, Su IJ, Yu CK. . Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007; 81:10310 - 5; http://dx.doi.org/10.1128/JVI.00372-07; PMID: 17626076</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00372-07</ArticleId><ArticleId IdType="pmc">PMC2045469</ArticleId><ArticleId IdType="pubmed">17626076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST. . Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 2006; 24:2944 - 51; http://dx.doi.org/10.1016/j.vaccine.2005.12.047; PMID: 16448730</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. . The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21 - 50; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141702; PMID: 17029568</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141702</ArticleId><ArticleId IdType="pubmed">17029568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeharju K, Knip M, Virtanen SM, Savilahti E, Tauriainen S, Koskela P, Akerblom HK, Hy&#xf6;ty H, Finnish TRIGR Study Group. . Maternal antibodies in breast milk protect the child from enterovirus infections. Pediatrics 2007; 119:941 - 6; http://dx.doi.org/10.1542/peds.2006-0780; PMID: 17473095</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-0780</ArticleId><ArticleId IdType="pubmed">17473095</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. . Glycosylation and the immune system. Science 2001; 291:2370 - 6; http://dx.doi.org/10.1126/science.291.5512.2370; PMID: 11269318</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.291.5512.2370</ArticleId><ArticleId IdType="pubmed">11269318</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarti BK, Kong WP, Wu BY, Yang ZY, Friborg J, Ling X, King SR, Montefiori DC, Nabel GJ. . Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002; 76:5357 - 68; http://dx.doi.org/10.1128/JVI.76.11.5357-5368.2002; PMID: 11991964</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.11.5357-5368.2002</ArticleId><ArticleId IdType="pmc">PMC137015</ArticleId><ArticleId IdType="pubmed">11991964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchausp&#xe9; G. . Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 2001; 75:12088 - 97; http://dx.doi.org/10.1128/JVI.75.24.12088-12097.2001; PMID: 11711599</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.24.12088-12097.2001</ArticleId><ArticleId IdType="pmc">PMC116104</ArticleId><ArticleId IdType="pubmed">11711599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, et al. . . A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013; 31:2471 - 6; http://dx.doi.org/10.1016/j.vaccine.2013.03.015; PMID: 23541623</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ. . Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013; 9:1701 - 5; http://dx.doi.org/10.4161/hv.24949; PMID: 23744508</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al. . . Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013; 8:e54451; http://dx.doi.org/10.1371/journal.pone.0054451; PMID: 23372725</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. . Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30:3295 - 303; http://dx.doi.org/10.1016/j.vaccine.2012.03.010; PMID: 22426327</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H, Li L, Liang ZL, Zhu FC. . Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012; 8:668 - 74; http://dx.doi.org/10.4161/hv.19521; PMID: 22634437</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.19521</ArticleId><ArticleId IdType="pubmed">22634437</ArticleId></ArticleIdList></Reference><Reference><Citation>A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children. Mar 10, 2013 2013. http://www.deepdyve.com/lp/clinical-trials/a-protected-studyof-inactivated-ev71-vaccine-human-diploid-cellkmb-679kOYq0nc/1.</Citation></Reference><Reference><Citation>Positive topline results from Phase III trial of Enterovirus 71 vaccine (Sinovac Biotech) against Hand, Foot and Mouth Disease. 2013. http://www.epgonline.org/news /2013/Mar/Positive-toplineresults-fromPhase.cfm.</Citation></Reference><Reference><Citation>Li JX, Meng FY, Liang ZL, Mao QY, Zhu FC. . How to understand the efficacy measurements for enterovirus type 71 vaccine?. [Epub ahead of print] Hum Vaccin Immunother 2013; 10; PMID: 24280898</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130280</ArticleId><ArticleId IdType="pubmed">24280898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarkowska A, Jakubowska A. . [Pichia pastoris as an expression system for recombinant protein production]. Postepy Biochem 2013; 59:315 - 21; PMID: 24364214</Citation><ArticleIdList><ArticleId IdType="pubmed">24364214</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogl T, Hartner FS, Glieder A. . New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris. Curr Opin Biotechnol 2013; 24:1094 - 101; http://dx.doi.org/10.1016/j.copbio.2013.02.024; PMID: 23522654</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2013.02.024</ArticleId><ArticleId IdType="pmc">PMC3841573</ArticleId><ArticleId IdType="pubmed">23522654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>